We are live on ! Find out more
RSCM

Rock Springs Capital Management Portfolio holdings

AUM $1.7B
1-Year Est. Return 93.03%
This Fund
S&P 500
This Quarter Est. Return
+20.34%
1 Year Est. Return
+93.03%
3 Year Est. Return
+228.43%
5 Year Est. Return
+368.14%
10 Year Est. Return
+4,607.77%
AUM
$4.16B
AUM Growth
+$284M
Cap. Flow
+$60M
Cap. Flow %
1.44%
Top 10 Hldgs %
34.47%
Holding
129
New
1
Increased
41
Reduced
24
Closed
9

Top Buys

Rank Stock Value
1
AMLX icon
Amylyx Pharmaceuticals
AMLX
+$29.3M
2
RXDX
Prometheus Biosciences, Inc. Common Stock
RXDX
+$25M
3
BAX icon
Baxter International
BAX
+$21.2M
4
BPMC
Blueprint Medicines
BPMC
+$16.9M
5
IRON icon
Disc Medicine
IRON
+$16.9M

Top Sells

Rank Stock Value
1
CVET
Covetrus, Inc. Common Stock
CVET
+$35.1M
2
SWAV
Shockwave Medical, Inc. Common Stock
SWAV
+$16.4M
3
ARVN icon
Arvinas
ARVN
+$12.5M
4
GOSS icon
Gossamer Bio
GOSS
+$9.97M
5
OHPAU
Orion Acquisition Corp. Unit
OHPAU
+$9.87M

Sector Composition

Rank Sector Weight
1 Healthcare 97.77%
2 Consumer Staples 0.83%
3 Industrials 0.36%
4 Financials 0.04%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MRSN
51
DELISTED
Mersana Therapeutics
MRSN
$24M 0.58%
164,152
+1,114
+0.7% +$188K
SWAV
52
DELISTED
Shockwave Medical, Inc. Common Stock
SWAV
$23.7M 0.57%
115,100
-65,000
-36% -$16.4M
LEGN icon
53
Legend Biotech
LEGN
$4B
$22.5M 0.54%
450,466
– –
BCRX icon
54
BioCryst Pharmaceuticals
BCRX
$2.51B
$21.7M 0.52%
1,890,737
+178,230
+10% +$2.22M
AZTA icon
55
Azenta
AZTA
$1.54B
$20.5M 0.49%
351,500
+21,300
+6% +$1.09M
CYTK icon
56
Cytokinetics
CYTK
$10.5B
$20.3M 0.49%
443,000
– –
TVTX icon
57
Travere Therapeutics
TVTX
$5.74B
$20M 0.48%
951,650
– –
IMTX icon
58
Immatics
IMTX
$1.33B
$19.8M 0.48%
2,274,784
+593,560
+35% +$6.14M
DVAX
59
DELISTED
Dynavax Technologies
DVAX
$19.3M 0.46%
1,813,758
+130,400
+8% +$1.52M
CLDX icon
60
Celldex Therapeutics
CLDX
$3.37B
$18.8M 0.45%
421,504
-100
-0% -$3.57K
CNMD icon
61
CONMED
CNMD
$1.48B
$18.2M 0.44%
205,000
-28,000
-12% -$2.32M
ANAB icon
62
AnaptysBio
ANAB
$1.64B
$17.9M 0.43%
576,600
– –
COLL icon
63
Collegium Pharmaceutical
COLL
$882M
$16.8M 0.4%
725,000
– –
WRBY icon
64
Warby Parker
WRBY
$3.26B
$16.4M 0.4%
1,218,975
-90,500
-7% -$1.38M
ACCD
65
DELISTED
Accolade Inc
ACCD
$15.1M 0.36%
1,938,000
-336,000
-15% -$3.21M
CINC
66
DELISTED
CinCor Pharma, Inc. Common Stock
CINC
$13.7M 0.33%
1,116,578
-89,278
-7% -$2.13M
LFST icon
67
Lifestance Health
LFST
$4.55B
$13.3M 0.32%
2,700,000
+700,000
+35% +$4.33M
KDNY
68
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
$13.3M 0.32%
507,512
– –
FOLD
69
DELISTED
Amicus Therapeutics
FOLD
$13M 0.31%
1,063,806
+51,300
+5% +$578K
VERV
70
DELISTED
Verve Therapeutics
VERV
$10.8M 0.26%
558,837
– –
AURA icon
71
Aura Biosciences
AURA
$796M
$10.7M 0.26%
1,019,757
+4,000
+0.4% +$50.9K
RLAY icon
72
Relay Therapeutics
RLAY
$4.37B
$10.1M 0.24%
673,966
+55,699
+9% +$1.07M
HCAT icon
73
Health Catalyst
HCAT
$127M
$9.88M 0.24%
929,900
+49,900
+6% +$482K
FOCL
74
EDAP TMS S.A.
FOCL
$228M
$9.7M 0.23%
910,000
– –
AMYT
75
DELISTED
Amryt Pharma plc American Depositary Shares
AMYT
$9.68M 0.23%
1,325,625
– –
1 2
3
4 5

Similar funds

ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
BCM
BlueCrest Capital Management St Helier, Jersey $1.69B AUM 20.01% 1-Year Est. Return
PP
PDT Partners New York $1.69B AUM 74.01% 1-Year Est. Return
GAM
Goldentree Asset Management New York $1.69B AUM 10.69% 1-Year Est. Return
FACM
Forest Avenue Capital Management Miami, Florida $1.69B AUM 104.84% 1-Year Est. Return
RMC
Ribbit Management Company Palo Alto, California $1.68B AUM 40.61% 1-Year Est. Return
JIP
Jaffetilchin Investment Partners Tampa, Florida $1.68B AUM 22.81% 1-Year Est. Return
II
Inspire Investing Meridian, Idaho $1.71B AUM 31.76% 1-Year Est. Return

Rock Springs Capital Management's Q4 2022 Portfolio in Review

As of Q4 2022, Rock Springs Capital Management held 129 positions worth $4.16B, up 7.3% from $3.87B the previous quarter. Its ten largest holdings account for 34% of the portfolio.

Rock Springs Capital Management's Q4 2022 filing shows 1 new, 41 increased, 24 reduced and 9 closed positions. Its largest new stake was Disc Medicine: 339,497 shares worth $6.75M. The largest sale was Covetrus, Inc. Common Stock, an estimated $35.1M.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, up from 97% a quarter earlier, followed by Consumer Staples and Industrials.

  • Rock Springs Capital Management's largest Q4 2022 buy was Disc Medicine: 339,497 shares worth $6.75M.
  • Rock Springs Capital Management added most to Amylyx Pharmaceuticals in Q4 2022, an estimated $29.3M increase.
  • Rock Springs Capital Management's biggest Q4 2022 reduction was Shockwave Medical, Inc. Common Stock, cutting an estimated $16.4M.
  • Rock Springs Capital Management fully exited Covetrus, Inc. Common Stock in Q4 2022, selling an estimated $35.1M.
  • Rock Springs Capital Management's ten largest holdings make up 34% of its $4.16B portfolio in Q4 2022.
  • Rock Springs Capital Management opened 1 new position and closed 9 in Q4 2022.
  • Rock Springs Capital Management's portfolio value rose 7.3% quarter-over-quarter to $4.16B.

Based on Rock Springs Capital Management's 13F filing for Q4 2022, filed 14 Feb 2023.